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Targeting of cancer stem cells (CSCs) has the potential to address the recalcitrance of pancreatic cancer to
chemotherapy. In this issue of Cell Stem Cell, Lonardo et al. (2011) demonstrate that Nodal/Activin signaling
is crucial for the maintenance and tumor-initiating capacity of pancreatic CSCs.Pancreatic ductal adenocarcinoma
(PDAC) is notorious for its rapid recur-
rence after resection, propensity to
metastasize, and strong resistance to
chemotherapy, features commonly attrib-
uted to cancer stem cells (CSCs). PDAC
tumor cells enriched for surface expres-
sion of CD44+CD24+ESA+ (Li et al.,
2007), CD133+ (Hermann et al., 2007), or
CD44+c-METHigh (Li et al., 2011) harbor
phenotypic hallmarks of CSCs, including
tumor-initiation, self-renewal capacity,
and the ability to fully recapitulate the
phenotypic diversity of the primary tumor.
Pancreatic CSCs defined by one or more
of these markers are resistant to gemcita-
bine chemotherapy (Hermann et al., 2007;
Li et al., 2011; Mueller et al., 2009) and
uniquely able to metastasize (Hermann
et al., 2007; Li et al., 2011). In this issue
of Cell Stem Cell, Heeschen and col-
leagues (Lonardo et al., 2011) expand on
their prior work with CD133+ pancreatic
CSCs to show that Nodal/Activin sig-
naling is critical for the maintenance and
tumor-initiating capacity of pancreatic
CSCs and is a promising target for CSC-
directed therapy.
Nodal and Activin, members of the
TGFb superfamily, are morphogens that
promote differentiation during embryo-
genesis and paradoxically maintain em-
bryonic stem cell pluripotency (Bianco
et al., 2010; Pera and Tam, 2010). They
bind Activin-like type I (Alk4 and Alk7) or
II receptors (AcrRIIA and AcrRIIB) to
trigger phosphorylation of Smad2 and
Smad3, which in complex with Smad4
translocates to the nucleus and interacts
with cotranscriptional activators to drive
target gene expression, including the plu-ripotency genes Nanog and Oct4 (Bianco
et al., 2010; Pera and Tam, 2010) (Fig-
ure 1). Nodal and its coreceptor Cripto-1
are inappropriately expressed in various
human tumors and may promote on-
cogenesis by facilitating epithelial-to-
mesenchymal transition (EMT) or CSC
phenotype (Bianco et al., 2010).
Lonardo et al. (2011) examined pancre-
atic CSCs from both cell lines and primary
tumor samples and found them to be
highly enriched for Nodal/Activin signaling
as measured biochemically and by gene
expression of pathway regulators or its
downstream targets. Mechanistically,
CSC renewal (as measured by in vitro
sphere formation) was enhanced by re-
combinant Nodal or Activin treatment
and blocked by the Alk receptor inhibitor
SB431542 (specific for Alk4, Alk5, and
Alk7) or Nodal-specific feedback inhibitor
Lefty. Moreover, shRNA-mediated knock-
down of Nodal, Alk4, or Smad4 blocked
sphere formation in vitro and tumor initia-
tion in vivo.
Examining the potential clinical implica-
tions of these findings, the authors treated
L3.6pl pancreatic cells ex vivo with the
Alk receptor inhibitor SB431542. While
this treatment depleted CD133+ CSCs,
this effect was reversible and failed to
inhibit tumor formation in an orthotopic
xenograft model. In contrast, combined
treatment with SB431542 and gemcita-
bine irreversibly depleted CD133+ cells
and inhibited in vivo tumor formation, indi-
cating SB431542 sensitized pancreatic
CSCs to gemcitabine, probably by in-
ducing differentiation. This result parallels
previous studies showing concurrent use
of gemcitabine more effectively blockedCell Stem Cell 9,tumorigenicity when pancreatic CSCs
were targeted by pharmacological inhibi-
tion of mTOR (Mueller et al., 2009) or
Met (Li et al., 2011). Combined treatment
regimens that render pancreatic CSCs
susceptible to cytotoxic chemotherapy
appear advantageous in that they (1) can
be used for a shorter duration to limit
toxicity to normal stem cells and (2)
account for tumor cells that dynamically
and reversibly transit between stem and
nonstem cell states.
Concurrent targeting of pancreatic
tumor stroma appears essential for the
effective treatment for PDAC. The densely
fibrotic stroma of PDAC cause hypoperfu-
sion and hypoxia, which in turn compro-
mise intratumoral drug delivery and pro-
mote EMT and a CSC-permissive niche
(Neesse et al., 2011). Along these lines,
Lonardo et al. (2011) targeted Nodal and
Activin in a more relevant preclinical
model of pre-established orthotopic xe-
nograft tumors composed of primary
human PDAC tumors and their associated
stroma. In contrast to the aforementioned
orthotopic model with L3.6pl cells, tumor
growth of established human PDAC could
only be arrested when SB431542 was
used in combination with gemcitabine
and the Hedgehog (Hh) pathway inhibitor
CUR199691. The addition of the Hh inhib-
itor reduced tumor stroma, significantly
increased intratumoral concentrations
of SB431542, and markedly depleted
CD133+ and CD44+ CSCs. Intriguingly,
inhibition of Hh signaling may be impor-
tant for depleting stromal cells involved
in paracrine Nodal/Activin signaling. The
authors found Nodal-expressing pancre-
atic stellate cells enhanced in vitro sphereNovember 4, 2011 ª2011 Elsevier Inc. 383
Figure 1. Nodal/Activin Signaling Maintains PDAC
Stem Cells in the Tumor Stromal Microenvironment
Inhibition of Alk receptor inhibitor by SB431542 blocks auto-
crine and potential paracrine Nodal signaling, sensitizing
CSCs to chemotherapy. Inhibition of the Hedgehog pathway
with CUR199691 disrupts the stroma and also may directly
influence CSCs.
Cell Stem Cell
Previewsformation in an Alk4/Alk7-depen-
dent manner, leading them to spec-
ulate that the pancreatic CSC
phenotype may also be linked to
paracrine-mediated Nodal/Activin
signaling at the tumor-stromal inter-
face (Figure 1). This hypothesis still
needs to be directly addressed
in vivo, as does the question of
whether or not Nodal/Activin trig-
gers important signaling in the
stromal itself.
An important issue raised by this
study is whether the function of
Nodal/Activin signaling might vary
by tumor on the basis of its strength
of activation or other extrinsic fac-
tors. For instance, differences in
the levels of Nodal/Activin signaling
in murine ES cells drive qualitatively
distinct patterns of gene expression
linked to either pluripotency or
differentiation (Lee et al., 2011).
Nodal/Activin signaling is further
influenced by its cotranscriptional
activators and crosstalk with otherdevelopmental signaling pathways (Bianco
et al., 2010; Pera and Tam, 2010). Thus,
these factors have the potential to toggle
the functional polarity of Nodal/Activin
signaling between differentiation and
pluripotency.
Nodal/Activin signaling joins a growing
list of development pathways that are de-
regulated in pancreatic CSCs, including
Hedgehog (Li et al., 2007), Bmi-1 (Lee
et al., 2008), mTOR (Mueller et al.,
2009), and c-MET (Li et al., 2011). The
relative contribution of these or other
signaling pathways to the CSC pheno-
type across the full spectrum of patient
tumors is currently unknown and will be
important for determining the feasibility384 Cell Stem Cell 9, November 4, 2011 ª20of any CSC-targeted therapy. In this re-
gard, Lonardo et al. (2011) provide
biochemical and phenotypic evidence
that Nodal/Activin signaling (as well as
its inhibition by SB431542) is depen-
dent on intact Smad4 function, a gene
mutated in a majority of PDAC. Despite
an apparent functional requirement for
Smad4, certain PDAC tumors with
Smad4 mutations were found to be
responsive to SB431542 for reasons
that remain unclear. Ultimately, the
successful clinical deployment of Nodal/
Activin-targeted therapy will hinge on
understanding how Smad4 (and other
factors able to impinge upon Nodal/Acti-
vin signaling) dictate treatment response11 Elsevier Inc.in PDAC. Even so, the findings by
Lonardo et al. (2011) offer a new
and important avenue for transla-
tional research with the potential to
efficaciously treat pancreatic
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